FDA authorizes booster shot for Novavax’s Covid-19 vaccine
Oct. 19, 2022 (STAT) – The Food and Drug Administration announced Wednesday that it has authorized a booster shot for Novavax’s Covid-19 vaccine.
Unlike the latest boosters from Pfizer-BioNTech and Moderna, which target both the original strain of SARS-CoV-2 and the Omicron BA.4/5 variants, the Novavax booster only targets the original strain. The company announced in late May that it was studying an Omicron-targeting strain, as well as a bivalent booster. But results of that work have not been revealed to date.
The booster shot is authorized for people 18 and older who, for medical or accessibility reasons, cannot take one of the bivalent messenger RNA Covid boosters, or who otherwise would not take a booster.